Chaoliu L. Dai - Publications

Prognostic Value of the PET/CT-Derived Maximum Standardized Uptake Value Combined with the Neutrophil-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Undergoing Hepatectomy.

Journal: Current oncology (Toronto, Ont.)

Published: November 27, 2025

AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: September 03, 2025

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Journal: Hepatobiliary surgery and nutrition

Published: February 28, 2025

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Journal: Bioscience trends

Published: December 25, 2024

China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).

Journal: Liver cancer

Published: November 04, 2024

Development and validation of a new prognostic tool for hepatocellular carcinoma undergoing resection: The Weighted Alpha-Fetoprotein Tumor Burden Score (WATS).

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: August 19, 2024

Chinese expert consensus on clinical application of molecularly targeted drugs for hepatocellular carcinoma (2022 edition).

Journal: Chinese medical journal

Published: March 23, 2024

A Survey of Clinical Practices for Hepatocellular Carcinoma Among Experts at Tertiary Hospitals in China From 2020 to 2021.

Journal: Cancer innovation

Published: February 26, 2024

Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition).

Journal: Liver cancer

Published: January 31, 2024

HHLA2 promotes hepatoma cell proliferation, migration, and invasion via SPP1/PI3K/AKT signaling pathway.

Journal: Molecular carcinogenesis

Published: December 01, 2023

The tumor burden score may be a discriminator in microwave ablation versus liver resection for hepatocellular carcinoma within the Milan criteria: a propensity score matching and inverse probability of treatment weighting study.

Journal: Frontiers in oncology

Published: October 31, 2023

A Novel Prognostic Nomogram Based on TIGIT and NKG2A Can Predict Relapse-Free Survival of Hepatocellular Carcinoma After Hepatectomy.

Journal: Cancer medicine

Published: October 09, 2023